Paper Details

  1. Home
  2. Paper Details

Recurrent hyperglycemic hyperosmolar state after re-administration of dose-reduced ceritinib, an anaplastic lymphoma kinase inhibitor.

Author: MasuzawaMasahiro, MiyoshiYuka, NishidaAi, OgawaOsamu

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Overview

This case report describes a patient who experienced recurrent hyperglycemic hyperosmolar state (HHS) after re-administration of ceritinib, a second-generation anaplastic lymphoma kinase (ALK) inhibitor. While hyperglycemia is a known adverse event of ceritinib, the mechanism is unclear. The study suggests that ceritinib can cause HHS and that recurrence may occur even after dose reduction.
Paper Details　
Original Abstract of the Article :
Ceritinib is a second-generation anaplastic lymphoma kinase (ALK) inhibitor with clinical activity in crizotinib-resistant ALK-positive non-small cell lung cancer and in treatment-naïve ALK-positive disease. Hyperglycemia is a known adverse event, but the mechanism by which ceritinib causes hypergly...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7790956/

データ提供：米国国立医学図書館（NLM）

Ceritinib and Hyperglycemia: A Tale of Two Medications in the Desert of Cancer Treatment

This case report presents a patient who experienced recurrent hyperglycemic hyperosmolar state (HHS) after re-administration of ceritinib, a medication used for treating anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer. The study investigates the potential link between ceritinib and HHS, highlighting the importance of monitoring blood glucose levels in patients receiving this medication.

Navigating the Challenges of Cancer Treatment: A Desert of Potential Side Effects

The case report demonstrates the potential for ceritinib to induce HHS, a serious condition that can lead to significant complications. This finding underscores the need for careful patient monitoring and prompt intervention when blood glucose levels are elevated.

A Cautious Approach to Ceritinib Therapy: Finding the Right Path Through the Desert of Side Effects

This research highlights the potential risks associated with ceritinib therapy, particularly for patients with underlying diabetes. It emphasizes the importance of careful patient selection, dose adjustment, and close monitoring of blood glucose levels to minimize the risk of HHS and other adverse events.

Dr.Camel's Conclusion

The desert of cancer treatment is fraught with challenges, and navigating these complexities requires a vigilant approach. This case report serves as a reminder that even promising medications can have unexpected side effects. Careful monitoring, personalized therapy, and proactive communication are crucial for ensuring the safety and well-being of patients undergoing cancer treatment.

Date :
  1. Date Completed n.d.
  2. Date Revised 2021-06-04
Further Info :

Pubmed ID

33479588

DOI: Digital Object Identifier

PMC7790956

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.